18 October 2020>: Clinical Research
Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
Yongxiang Zhang ABCDE , Yuechuan Li AEFG* , Zhen Ye BD , Hui Ma CFDOI: 10.12659/MSM.925278
Med Sci Monit 2020; 26:e925278
Table 3 Comparison of pulmonary function between COPD group and control group.
Groups | Control (n=20) | COPD | |||
---|---|---|---|---|---|
Total (n=40) | Mild (n=8) | Moderate (n=24) | Severe (n=8) | ||
FEV (L) | 3.56±0.74 | 2.11±0.57** | 2.24±0.12** | 2.10±0.16** | 2.03±0.17** |
FVC (L) | 4.09±0.84 | 3.60±0.17** | 3.66±0.54 | 3.60±0.56* | 3.53±0.68** |
FEV/FVC (%) | 87.26±2.60 | 60.16±7.93** | 61.95±6.58** | 59.49±8.83** | 60.38±671** |
FEV%pre | 90.30±5.07 | 63.71±2.20** | 82.30±3.07* | 63.33±7.53,** | 45.25±3.71,,** |
DLCO%pre | 84.96±13.03 | 75.83±15.30* | 81.68±10.03 | 78.65±14.98 | 61.51±12.83,,** |
FEV – forced expiratory volume in 1 second; FVC – forced vital capacity; DLCO – carbon monoxide diffusing capacity; Control group, * ** ## && |